S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Ovid Therapeutics (OVID) Earnings Date, Estimates & Call Transcripts

$3.23
+0.02 (+0.62%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 3Estimated
Actual EPS
(Mar. 8)
-$0.22 Missed By -$0.05
Consensus EPS
(Mar. 8)
-$0.17
Skip Charts & View Estimated and Actual Earnings Data

OVID Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

OVID Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ovid Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.19)($0.19)($0.19)
Q2 20241($0.19)($0.19)($0.19)
Q3 20241($0.18)($0.18)($0.18)
Q4 20241($0.19)($0.19)($0.19)
FY 20244($0.75)($0.75)($0.75)

OVID Earnings Date and Information

Ovid Therapeutics last issued its quarterly earnings data on March 8th, 2024. The reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.05. The company earned $0.14 million during the quarter, compared to analyst estimates of $0.10 million. Ovid Therapeutics has generated ($0.75) earnings per share over the last year (($0.75) diluted earnings per share). Earnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.20) per share. Ovid Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 3rd, 2024 based off prior year's report dates.

Ovid Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/3/2024
Estimated)
------- 
3/8/2024Q4 2023($0.17)($0.22)($0.05)($0.22)$0.10 million$0.14 million
11/3/2023Q3 2023($0.18)($0.16)+$0.02($0.16)$0.09 million$0.11 million
8/4/2023Q2 2023($0.21)($0.18)+$0.03($0.18)$0.09 million$0.08 million
5/5/2023Q1 2023($0.18)($0.19)($0.01)($0.19)$0.06 million$0.07 million
3/13/2023Q4 2022($0.17)($0.16)+$0.01($0.16)-$0.05 million
11/8/2022Q3 2022($0.21)($0.17)+$0.04($0.17)-$0.01 million
8/9/2022Q2 2022($0.23)($0.21)+$0.02($0.21)--
5/10/2022Q1 2022$1.17($0.23)($1.40)($0.23)-$1.45 million    
3/15/2022Q4 2021($0.17)($0.38)($0.21)($0.38)--
11/10/2021Q3 2021($0.19)($0.17)+$0.02($0.17)--
8/16/2021Q2 2021($0.16)($0.23)($0.07)($0.23)--
5/13/2021Q1 2021$1.45$2.53+$1.08$2.53$2.21 million$208.38 million

Ovid Therapeutics Earnings - Frequently Asked Questions

When is Ovid Therapeutics's earnings date?

Ovid Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 3rd, 2024 based off last year's report dates. Learn more on OVID's earnings history.

Did Ovid Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Ovid Therapeutics (NASDAQ:OVID) missed the analysts' consensus estimate of ($0.17) by $0.05 with a reported earnings per share (EPS) of ($0.22). Learn more on analysts' earnings estimate vs. OVID's actual earnings.

How much revenue does Ovid Therapeutics generate each year?

Ovid Therapeutics (NASDAQ:OVID) has a recorded annual revenue of $390,000.00.

How much profit does Ovid Therapeutics generate each year?

Ovid Therapeutics (NASDAQ:OVID) has a recorded net income of -$52.34 million. OVID has generated -$0.75 earnings per share over the last four quarters.

What is Ovid Therapeutics's EPS forecast for next year?

Ovid Therapeutics's earnings are expected to grow from ($0.65) per share to ($0.20) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:OVID) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners